382 related articles for article (PubMed ID: 12444809)
1. Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study.
Sjögren MJ; Hellström PT; Jonsson MA; Runnerstam M; Silander HC; Ben-Menachem E
J Clin Psychiatry; 2002 Nov; 63(11):972-80. PubMed ID: 12444809
[TBL] [Abstract][Full Text] [Related]
2. Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year.
Merrill CA; Jonsson MA; Minthon L; Ejnell H; C-son Silander H; Blennow K; Karlsson M; Nordlund A; Rolstad S; Warkentin S; Ben-Menachem E; Sjögren MJ
J Clin Psychiatry; 2006 Aug; 67(8):1171-8. PubMed ID: 16965193
[TBL] [Abstract][Full Text] [Related]
3. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.
Doraiswamy PM; Bieber F; Kaiser L; Krishnan KR; Reuning-Scherer J; Gulanski B
Neurology; 1997 Jun; 48(6):1511-7. PubMed ID: 9191757
[TBL] [Abstract][Full Text] [Related]
4. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
[TBL] [Abstract][Full Text] [Related]
5. Repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: clinical experience.
Rabey JM; Dobronevsky E
J Neural Transm (Vienna); 2016 Dec; 123(12):1449-1455. PubMed ID: 27631152
[TBL] [Abstract][Full Text] [Related]
6. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.
Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T
J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978
[TBL] [Abstract][Full Text] [Related]
7. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts.
Cano SJ; Posner HB; Moline ML; Hurt SW; Swartz J; Hsu T; Hobart JC
J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1363-8. PubMed ID: 20881017
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders.
George MS; Ward HE; Ninan PT; Pollack M; Nahas Z; Anderson B; Kose S; Howland RH; Goodman WK; Ballenger JC
Brain Stimul; 2008 Apr; 1(2):112-21. PubMed ID: 20633378
[TBL] [Abstract][Full Text] [Related]
9. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
10. How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?
Balsis S; Benge JF; Lowe DA; Geraci L; Doody RS
Clin Neuropsychol; 2015; 29(7):1002-9. PubMed ID: 26617181
[TBL] [Abstract][Full Text] [Related]
11. Vagus nerve stimulation in 15 children with therapy resistant epilepsy; its impact on cognition, quality of life, behaviour and mood.
Hallböök T; Lundgren J; Stjernqvist K; Blennow G; Strömblad LG; Rosén I
Seizure; 2005 Oct; 14(7):504-13. PubMed ID: 16176878
[TBL] [Abstract][Full Text] [Related]
12. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
13. A naturalistic study of galantamine for Alzheimer's disease.
Brodaty H; Woodward M; Boundy K; Barnes N; Allen G;
CNS Drugs; 2006; 20(11):935-43. PubMed ID: 17044730
[TBL] [Abstract][Full Text] [Related]
14. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
16. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.
Kennedy J; Deberdt W; Siegal A; Micca J; Degenhardt E; Ahl J; Meyers A; Kaiser C; Baker RW
Int J Geriatr Psychiatry; 2005 Nov; 20(11):1020-7. PubMed ID: 16250069
[TBL] [Abstract][Full Text] [Related]
18. Repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease.
Nguyen JP; Suarez A; Kemoun G; Meignier M; Le Saout E; Damier P; Nizard J; Lefaucheur JP
Neurophysiol Clin; 2017 Feb; 47(1):47-53. PubMed ID: 28161090
[TBL] [Abstract][Full Text] [Related]
19. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative.
Song X; Mitnitski A; Zhang N; Chen W; Rockwood K;
J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):71-8. PubMed ID: 23123510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
